Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease

This publication has 29 references indexed in Scilit:

• Angiogenesis
  Circulation, 2005
• Design of the Del-1 for Therapeutic Angiogenesis Trial (DELTA-1), a Phase II Multicenter, Double-Blind, Placebo-Controlled Trial of VLTS-589 in Subjects with Intermittent Claudication Secondary to Peripheral Arterial Disease
  Human Gene Therapy, 2004
• Evaluating effects of method of administration on Walking Impairment Questionnaire
  Journal of Vascular Surgery, 2003
• Progress and prospects: naked DNA gene transfer and therapy
  Gene Therapy, 2003
• Del1 mediates VSMC adhesion, migration, and proliferation through interaction with integrin α_vβ₃
  American Journal of Physiology-Heart and Circulatory Physiology, 2002
• Electroporation-Facilitated Delivery of Plasmid DNA in Skeletal Muscle: Plasmid Dependence of Muscle Damage and Effect of Poloxamer 188
  Molecular Therapy, 2001
• SF-36 Health Survey Update
  Spine, 2000
• A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle
  Gene Therapy, 2000
• Del1 Induces Integrin Signaling and Angiogenesis by Ligation of αVβ3
  Published by Elsevier ,1999
• Cloning and characterization of developmental endothelial locus-1: An embryonic endothelial cell protein that binds the αvβ3 integrin receptor
  Genes & Development, 1998